Abstract Number: 0351 • ACR Convergence 2020
Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients
Background/Purpose: In the PsABio study (NCT02627768), real-world data from patients with PsA showed comparable clinical results after treatment with ustekinumab (UST, an anti-p40 IL-12/23 inhibitor)…Abstract Number: 0359 • ACR Convergence 2020
Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: Axial disease in psoriatic arthritis (PsA) has been reported to occur in anywhere from 25% to 75% of PsA patients (pts). It can be…Abstract Number: 0414 • ACR Convergence 2020
Clinical Characteristics of an Internet-Based Cohort of Participants with a Self-Reported Diagnosis of Cryoglobulinemic Vasculitis or IgA Vasculitis
Background/Purpose: Cyroglobulinemic vasculitis (CV) and IgA vasculitis are forms of small-vessel vasculitis characterized by immune complex deposition. The purpose of this study was to a)…Abstract Number: 0416 • ACR Convergence 2020
IgG4-related Retroperitoneal Fibrosis. Retrospective Cohort
Background/Purpose: The spectrum of IgG4-related disease (IgG4-RD) includes many diseases that were thought to be confined to a single organ, as the retroperitoneal fibrosis. Many…Abstract Number: 0676 • ACR Convergence 2020
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…Abstract Number: 0717 • ACR Convergence 2020
Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies
Background/Purpose: CLIPPER is an ongoing, 8-year, phase 3b, multicenter, open-label study of the safety and efficacy of etanercept in the treatment of juvenile idiopathic arthritis…Abstract Number: 1080 • ACR Convergence 2020
Sensitivity and Specificity of the 2017 EULAR/ACR Criteria for Idiopathic Inflammatory Myopathies in a Cohort of Patients from Latin America
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterized by muscle inflammation and internal organ involvement. The Bohan & Peter (B&P) criteria…Abstract Number: 1511 • ACR Convergence 2020
Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…Abstract Number: 1609 • ACR Convergence 2020
The Accuracy of Administrative Health Data for Identifying Patients with Rheumatoid Arthritis: A Validation Study Using Medical Records in Western Australia
Background/Purpose: The use of large administrative health datasets is increasingly important in Rheumatology for disease trends and outcome research. We established the West Australian Rheumatic…Abstract Number: PP01 • ACR Convergence 2020
Impacting Change Through Facilitation and Advocacy for Lupus
Background/Purpose: My story started as one of disbelief in 2009 with my Lupus diagnosis. How could a woman in the prime of her career be…
ACR Meeting Abstracts